BlackRock Fund Advisors’s Gyre Therapeutics GYRE Stock Holding History

BlackRock Fund Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$0	Hold	6	–	–	﹤0.01%	4246
2016 Q3	$1K	Hold	6	–	–	﹤0.01%	4212
2016 Q2	$1K	Sell	6 -83	-93%	-$14.2K	﹤0.01%	4267
2016 Q1	$17K	Sell	89 -4	-4%	-$964	﹤0.01%	3910
2015 Q4	$33K	Sell	93 -1	-1%	-$393	﹤0.01%	3926
2015 Q3	$49K	Sell	94 -2	-2%	-$3.05K	﹤0.01%	3829
2015 Q2	$212K	Sell	96 -8	-8%	-$16K	﹤0.01%	3509
2015 Q1	$244K	Sell	104 -8	-7%	-$16.5K	﹤0.01%	3432
2014 Q4	$231K	Buy	112 +8	+8%	+$15.4K	﹤0.01%	3449
2014 Q3	$206K	Sell	104 -7	-6%	-$17.3K	﹤0.01%	3453
2014 Q2	$394K	Sell	111 -889	-89%	-$2.9M	﹤0.01%	3256
2014 Q1	$3.74M	Buy	1,000 +8	+0.8%	+$29.6K	﹤0.01%	2975
2013 Q4	$3.24M	Sell	992 -505	-34%	-$1.99M	﹤0.01%	3033
2013 Q3	$6.26M	Buy	1,497 +150	+11%	+$604K	﹤0.01%	2643
2013 Q2	$4.53M	Buy	+1,347	New	+$5.13M	﹤0.01%	2749

Other funds holding GYRE

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return

CCM

Colorado Capital Management Boulder, Colorado $293M AUM 22.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

BlackRock Fund Advisors's GYRE Position: Q4 2016 in Review

BlackRock Fund Advisors held its Gyre Therapeutics (GYRE) position steady in Q4 2016 at 6 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4246.

BlackRock Fund Advisors first reported a position in GYRE in Q2 2013 and has held it in 15 quarters since. The position peaked at $6.26M in Q3 2013. 27 funds tracked by Wall St. Rank hold GYRE as of Q4 2016.

BlackRock Fund Advisors held 6 shares of Gyre Therapeutics worth $0 as of Q4 2016.
BlackRock Fund Advisors left its Gyre Therapeutics share count unchanged in Q4 2016.
Gyre Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #4246 holding.
BlackRock Fund Advisors first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 15 quarters since.
BlackRock Fund Advisors's Gyre Therapeutics position peaked at $6.26M in Q3 2013.
27 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.